The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  • Sara Sanz-Blasco
  • Melina P. Bordone
  • Ana Damianich
  • Gimena Gomez
  • M. Alejandra Bernardi
  • Luciana Isaja
  • Irene R. Taravini
  • Diane P. Hanger
  • M. Elena Avale
  • Oscar S. Gershanik
  • Juan E. Ferrario
Article

Abstract

Dopamine replacement therapy with l-DOPA is the treatment of choice for Parkinson’s disease; however, its long-term use is frequently associated with l-DOPA-induced dyskinesia (LID). Many molecules have been implicated in the development of LID, and several of these have been proposed as potential therapeutic targets. However, to date, none of these molecules have demonstrated full clinical efficacy, either because they lie downstream of dopaminergic signaling, or due to adverse side effects. Therefore, discovering new strategies to reduce LID in Parkinson’s disease remains a major challenge. Here, we have explored the tyrosine kinase Fyn, as a novel intermediate molecule in the development of LID. Fyn, a member of the Src kinase family, is located in the postsynaptic density, where it regulates phosphorylation of the NR2B subunit of the N-methyl-d-aspartate (NMDA) receptor in response to dopamine D1 receptor stimulation. We have used Fyn knockout and wild-type mice, lesioned with 6-hydroxydopamine and chronically treated with l-DOPA, to investigate the role of Fyn in the induction of LID. We found that mice lacking Fyn displayed reduced LID, ΔFosB accumulation and NR2B phosphorylation compared to wild-type control mice. Pre-administration of saracatinib (AZD0530), an inhibitor of Fyn activity, also significantly reduced LID in dyskinetic wild-type mice. These results support that Fyn has a critical role in the molecular pathways affected during the development of LID and identify Fyn as a novel potential therapeutic target for the management of dyskinesia in Parkinson’s disease.

Keywords

Parkinson’s disease l-DOPA Dyskinesias Fyn NR2B Saracatinib 

Notes

Acknowledgments

This work has been entirely done with grants provided from non-profit foundations or organizations as well as Argentine research institutions: EMBO short-term fellowship (JEF, 2012), IBRO Return Home Fellowship (JEF, 2013), ISN CAEN Return Home Grant (SSB, 2014), ANPCYT-PICT (OG 2011–1758), CONICET-PIP (JEF&IT, 2013–0401), and Michael J. Fox Foundation for Parkinson’s Research, Target Validation Spring 2014 (JEF & OG,). We thank Gustavo Murer for critical review of the manuscript, Mariano Saborido for obtaining preliminary data, and Soledad Campana and Natalia Baffa-Trasci for technical assistance.

Compliance with Ethical Standards

All surgical procedures and experimental manipulations were performed in accordance with the UK Home Office and the European Directive 2010/63/EU and approved by the Ethics Committee of “Facultad de Farmacia y Bioquímica” (Universidad de Buenos Aires, Argentina).

Conflict of Interest

The authors declare that they have no conflict of interests.

References

  1. 1.
    Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30:80–89.  https://doi.org/10.1002/mds.26125
  2. 2.
    Iravani MM, Jenner P (2011) Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 118:1661–1690.  https://doi.org/10.1007/s00702-011-0698-2
  3. 3.
    Bastide MF, Meissner WG, Picconi B et al (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 132:96–168.  https://doi.org/10.1016/j.pneurobio.2015.07.002
  4. 4.
    Darmopil S, Martin AB, De Diego IR et al (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66:603–613. https://doi.org/10.1016/j.biopsych.2009.04.025
  5. 5.
    Sawada H, Oeda T, Kuno S et al (2010) Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One 5:e15298.  https://doi.org/10.1371/journal.pone.0015298
  6. 6.
    Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem 118:1043–1055.  https://doi.org/10.1111/j.1471-4159.2011.07376.x
  7. 7.
    Thomas A, Iacono D, Luciano AL et al (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:141–143Google Scholar
  8. 8.
    Porras G, Berthet A, Dehay B et al (2013) PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122:3977–3989.  https://doi.org/10.1172/JCI59426DS1
  9. 9.
    Kim E, Sheng M (2004) PDZ domain proteins of synapses. Nat Rev Neurosci 5:771–781Google Scholar
  10. 10.
    Dunah AW, Sirianni AC, Fienberg AA et al (2004) Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 65:121–129Google Scholar
  11. 11.
    Trepanier CH, Jackson MF, MacDonald JF (2012) Regulation of NMDA receptors by the tyrosine kinase Fyn. FEBS J 279:12–19.  https://doi.org/10.1111/j.1742-4658.2011.08391.x
  12. 12.
    Kojima N, Ishibashi H, Obata K, Kandel ER (1998) Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice. Learn Mem 5:429–445Google Scholar
  13. 13.
    Ali DW, Salter MW (2001) NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr Opin Neurobiol 11:336–342.  https://doi.org/10.1016/S0959-4388(00)00216-6
  14. 14.
    Tezuka T, Umemori H, Akiyama T et al (1999) PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc Natl Acad Sci U S A 96:435–440Google Scholar
  15. 15.
    Gardoni F, Picconi B, Ghiglieri V et al (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26:2914–2922.  https://doi.org/10.1523/JNEUROSCI.5326-05.2006
  16. 16.
    Mabrouk OS, Mela F, Calcagno M et al (2013) GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. ACS Chem Neurosci 4:808–816.  https://doi.org/10.1021/cn400016d
  17. 17.
    Nutt JG, Gunzler SA, Kirchhoff T et al (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism. Mov Disord 23:1860–1866.  https://doi.org/10.1002/mds.22169
  18. 18.
    Quintana A, Melon C, Kerkerian-Le Goff L, et al (2010) Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-d-aspartate receptors. Eur J Neurosci 32:423–434. https://doi.org/10.1111/j.1460-9568.2010.07290.x
  19. 19.
    Errico F, Bonito-Oliva A, Bagetta V et al (2011) Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia. Exp Neurol 232:240–250.  https://doi.org/10.1016/j.expneurol.2011.09.013
  20. 20.
    Oh JD, Russell D, Vaughan CL, Chase TN (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 813:150–159.  https://doi.org/10.1016/S0006-8993(98)01049-X
  21. 21.
    Mao LM, Wang JQ (2015) Dopaminergic and cholinergic regulation of Fyn tyrosine kinase phosphorylation in the rat striatum in vivo. Neuropharmacology 99:491–499.  https://doi.org/10.1016/j.neuropharm.2015.08.017
  22. 22.
    Nakazawa T, Komai S, Tezuka T et al (2001) Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR??2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem 276:693–699.  https://doi.org/10.1074/jbc.M008085200
  23. 23.
    Usardi A, Pooler AM, Seereeram A et al (2011) Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J 278:2927–2937.  https://doi.org/10.1111/j.1742-4658.2011.08218.x
  24. 24.
    Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San DiegoGoogle Scholar
  25. 25.
    Francardo V, Recchia A, Popovic N et al (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neurobiol Dis 42:327–340.  https://doi.org/10.1016/j.nbd.2011.01.024
  26. 26.
    Kaufman AC, Salazar SV, Haas LT et al (2015) Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol 77:953–971.  https://doi.org/10.1002/ana.24394
  27. 27.
    Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110–123.  https://doi.org/10.1016/j.nbd.2004.01.007S0969996104000178
  28. 28.
    Lundblad M, Usiello A, Carta M et al (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194:66–75.  https://doi.org/10.1016/j.expneurol.2005.02.002
  29. 29.
    Francardo V, Recchia A, Popovic N et al (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neurobiol Dis 42:327–340.  https://doi.org/10.1016/j.nbd.2011.01.024
  30. 30.
    Delfino MA, Stefano AV, Ferrario JE et al (2004) Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res 152:297–306.  https://doi.org/10.1016/j.bbr.2003.10.009S0166432803003735
  31. 31.
    Larramendy C, Taravini IR, Saborido MD et al (2008) Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behav Brain Res 194:44–51.  https://doi.org/10.1016/j.bbr.2008.06.021
  32. 32.
    Cenci MA, Lundblad M (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice. Curr Protoc Neurosci. https://doi.org/10.1002/0471142301.ns0925s41
  33. 33.
    Taravini IR, Chertoff M, Cafferata EG et al (2011) Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Mol Neurodegener 6:40.  https://doi.org/10.1186/1750-1326-6-40
  34. 34.
    Ferrario JE, Rojas-Mayorquín AE, Saldaña-Ortega M et al (2008) Pleiotrophin receptor RPTP-ζ/β expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats. J Neurochem 107:443–452.  https://doi.org/10.1111/j.1471-4159.2008.05640.x
  35. 35.
    Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis 6:461–474.  https://doi.org/10.1006/nbdi.1999.0259
  36. 36.
    Prybylowski K, Chang K, Sans N et al (2005) The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47:845–857.  https://doi.org/10.1016/j.neuron.2005.08.016
  37. 37.
    Ruiz-Dediego I, Mellstrom B, Vallejo M et al (2015) Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry 77:95–105.  https://doi.org/10.1016/j.biopsych.2014.03.023
  38. 38.
    Suarez LM, Solis O, Carames JM et al (2014) L-DOPA treatment selectively restores spine density in dopamine receptor d2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 75:711–722.  https://doi.org/10.1016/j.biopsych.2013.05.006
  39. 39.
    Suarez LM, Solis O, Aguado C et al (2016) L-DOPA oppositely regulates synaptic strength and spine morphology in D1 and D2 striatal projection neurons in dyskinesia. Cereb Cortex 26:4253–4264.  https://doi.org/10.1093/cercor/bhw263
  40. 40.
    Panicker N, Saminathan H, Jin H et al (2015) Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson’s disease. J Neurosci 35:10058–10077.  https://doi.org/10.1523/JNEUROSCI.0302-15.2015
  41. 41.
    Herrera-Marschitz M, Arbuthnott G, Ungerstedt U (2010) The rotational model and microdialysis: significance for dopamine signalling, clinical studies, and beyond. Prog Neurobiol 90:176–189.  https://doi.org/10.1016/j.pneurobio.2009.01.005
  42. 42.
    Alvarez-Fischer D, Henze C, Strenzke C et al (2008) Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and α-synuclein-deleted mice. Exp Neurol 210:182–193.  https://doi.org/10.1016/j.expneurol.2007.10.012
  43. 43.
    Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401–415Google Scholar
  44. 44.
    Kalia LV, Gingrich JR, Salter MW (2004) Src in synaptic transmission and plasticity. Oncogene 23:8007–8016.  https://doi.org/10.1038/sj.onc.1208158
  45. 45.
    Ohnishi H, Murata Y, Okazawa H, Matozaki T (2011) Src family kinases: modulators of neurotransmitter receptor function and behavior. Trends Neurosci 34:629–637.  https://doi.org/10.1016/j.tins.2011.09.005
  46. 46.
    Pascoli V, Besnard A, Hervé D et al (2011) Cyclic adenosine monophosphate–independent tyrosine phosphorylation of NR2B mediates cocaine-induced extracellular signal-regulated kinase activation. Biol Psychiatry 69:218–227.  https://doi.org/10.1016/j.biopsych.2010.08.031
  47. 47.
    Pariser H, Ezquerra L, Herradon G et al (2005) Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 332:664–669Google Scholar
  48. 48.
    Kong M, Ba M, Liu C et al (2015) NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model. Behav Brain Res 282:46–53.  https://doi.org/10.1016/j.bbr.2014.12.059
  49. 49.
    Nash JE, Ravenscroft P, McGuire S et al (2004) The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson’s disease. Exp Neurol 188:471–479.  https://doi.org/10.1016/j.expneurol.2004.05.004
  50. 50.
    Mao L-M, Wang JQ (2016) Dopamine D2 receptors are involved in the regulation of Fyn and mGluR5 phosphorylation in the rat striatum in vivo. J Neurosci Res 4:329–38. https://doi.org/10.1002/jnr.23713
  51. 51.
    Babus LW, Little EM, Keenoy KE et al (2011) Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. Brain Res 1415:96–102.  https://doi.org/10.1016/j.brainres.2011.07.059
  52. 52.
    Morita A (2006) Regulation of dendritic branching and spine maturation by semaphorin3A-Fyn signaling. J Neurosci 26:2971–2980.  https://doi.org/10.1523/JNEUROSCI.5453-05.2006
  53. 53.
    Delfino M, Kalisch R, Czisch M et al (2007) Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 32:1911–1921.  https://doi.org/10.1038/sj.npp.1301329
  54. 54.
    Miyakawa T, Yagi T, Kagiyama A, Niki H (1996) Radial maze performance, open-field and elevated plus-maze behaviors in Fyn-kinase deficient mice: further evidence for increased fearfulness. Mol Brain Res 37:145–150.  https://doi.org/10.1016/0169-328X(95)00300-H
  55. 55.
    Fasano S, Bezard E, D’Antoni A et al (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 107:21824–21829.  https://doi.org/10.1073/pnas.1012071107
  56. 56.
    Feyder M, Södersten E, Santini E et al (2014) A role for mitogen- and stress-activated kinase 1 in L-DOPA-induced dyskinesia and {increment}FosB expression. Biol Psychiatry 79:362–371.  https://doi.org/10.1016/j.biopsych.2014.07.019
  57. 57.
    Nygaard HB, van Dyck CH, Strittmatter SM (2014) Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimers Res Ther 6:8.  https://doi.org/10.1186/alzrt238
  58. 58.
    Nygaard HB, Wagner AF, Bowen GS et al (2015) A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimers Res Ther 7:35Google Scholar
  59. 59.
    Kojima N, Wang J, Mansuy IM et al (1997) Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc Natl Acad Sci U S A 94:4761–4765Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Sara Sanz-Blasco
    • 1
    • 2
  • Melina P. Bordone
    • 1
    • 2
  • Ana Damianich
    • 1
    • 2
    • 3
  • Gimena Gomez
    • 1
    • 2
  • M. Alejandra Bernardi
    • 1
    • 2
  • Luciana Isaja
    • 1
    • 2
  • Irene R. Taravini
    • 1
    • 2
    • 4
  • Diane P. Hanger
    • 5
  • M. Elena Avale
    • 3
  • Oscar S. Gershanik
    • 1
    • 2
  • Juan E. Ferrario
    • 1
    • 2
  1. 1.Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina
  2. 2.Instituto de Investigaciones Farmacológicas (ININFA)CONICET - Universidad de Buenos AiresBuenos AiresArgentina
  3. 3.Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), “Dr. Héctor N. Torres”CONICETBuenos AiresArgentina
  4. 4.Facultad de BromatologíaUniversidad Nacional de Entre RíosGualeguaychuArgentina
  5. 5.Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical NeuroscienceInstitute of Psychiatry, Psychology & Neuroscience, King’s College London LondonUK

Personalised recommendations